We recently published a list of Was Jim Cramer Right About These 23 Stocks?. In this article, we are going to take a look at ...

StockNews.com upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) from a hold rating to a buy rating ...

The general mood among these heavyweight investors is divided, with 44% leaning bullish and 33% bearish. Among these notable options, 5 are puts, totaling $256,004, and 4 are calls, amounting to ...

In a report released today, David Amsellem from Piper Sandler maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report), with ...

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

The University of Wisconsin-Madison College Democrats and College Republicans are campaigning on abortion rights and public ...

Alvotech acquires Xbrane’s R&D operations and the biosimilar candidate XB003. Xbrane retains some pre-clinical development programs, that it intends to commercialize, and will continue operating as a ...

HighTower Advisors LLC raised its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 32.3% in ...

Amneal Pharmaceuticals, Inc. offers strong growth prospects with undervalued stock, rising revenues, reduced debt, and key ...

Stanley Druckenmiller, whose net worth is around $6.9 billion, made most of his fortune as a hedge fund manager, and became a ...

In two weeks, voters will decide whether the Wisconsin Supreme Court remains under liberal control or flips to a conservative majority with the ideological balance up for grabs ...

As a drugmaker depending heavily on sales of both branded and non-branded products, Teva has said that it is uniquely affected by how medicines are selected for the Medicare drug price negotiation | ...